193 related articles for article (PubMed ID: 29537138)
1. "Pre-emptive strike"-the case for early treatment of hepatic sinusoidal obstruction syndrome with defibrotide.
Rajagopal R; Phillips MB; Gottardo NG
Pediatr Blood Cancer; 2018 Jul; 65(7):e27036. PubMed ID: 29537138
[TBL] [Abstract][Full Text] [Related]
2. [Application of defibrotide in hepatic sinusoidal obstruction syndrome induced by hematopoietic stem cell transplantation].
Liu ZL; Wang Y; Liu YL; Zhang J
Zhonghua Gan Zang Bing Za Zhi; 2021 Jan; 29(1):92-96. PubMed ID: 33541030
[TBL] [Abstract][Full Text] [Related]
3. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.
Corbacioglu S; Richardson PG
Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848
[TBL] [Abstract][Full Text] [Related]
4. Hepatic sinusoidal obstruction syndrome during chemotherapy for childhood medulloblastoma: report of a case and review of the literature.
Kotecha RS; Buckland A; Phillips MB; Cole CH; Gottardo NG
J Pediatr Hematol Oncol; 2014 Jan; 36(1):76-80. PubMed ID: 24276042
[TBL] [Abstract][Full Text] [Related]
5. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Richardson PG; Triplett BM; Ho VT; Chao N; Dignan FL; Maglio M; Mohty M
Expert Rev Clin Pharmacol; 2018 Feb; 11(2):113-124. PubMed ID: 29301447
[TBL] [Abstract][Full Text] [Related]
6. Defibrotide treatment but not prophylaxis is useful in hepatic sinusoidal obstruction syndrome in children undergoing autologous stem cell transplant following high-dose chemotherapy: A single-center experience from the Royal Marsden Hospital, UK.
Roy Moulik N; Johnson I; Van Bruggen L; Petterson T; Mycroft J; Vaidya SJ
Pediatr Blood Cancer; 2020 Nov; 67(11):e28677. PubMed ID: 32865880
[TBL] [Abstract][Full Text] [Related]
7. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.
Kernan NA; Richardson PG; Smith AR; Triplett BM; Antin JH; Lehmann L; Messinger Y; Liang W; Hume R; Tappe W; Soiffer RJ; Grupp SA
Pediatr Blood Cancer; 2018 Oct; 65(10):e27269. PubMed ID: 29873895
[TBL] [Abstract][Full Text] [Related]
8. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
[TBL] [Abstract][Full Text] [Related]
9. Defibrotide Use in Vincristine-induced Hepatic Sinusoidal Obstruction Syndrome.
Tang C; Lindsay J; Gill A; Kerridge I
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):539-541. PubMed ID: 28842141
[No Abstract] [Full Text] [Related]
10. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
11. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.
Corbacioglu S; Cesaro S; Faraci M; Valteau-Couanet D; Gruhn B; Rovelli A; Boelens JJ; Hewitt A; Schrum J; Schulz AS; Müller I; Stein J; Wynn R; Greil J; Sykora KW; Matthes-Martin S; Führer M; O'Meara A; Toporski J; Sedlacek P; Schlegel PG; Ehlert K; Fasth A; Winiarski J; Arvidson J; Mauz-Körholz C; Ozsahin H; Schrauder A; Bader P; Massaro J; D'Agostino R; Hoyle M; Iacobelli M; Debatin KM; Peters C; Dini G
Lancet; 2012 Apr; 379(9823):1301-9. PubMed ID: 22364685
[TBL] [Abstract][Full Text] [Related]
12. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1471-1475. PubMed ID: 29477779
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Yang L; Qi J; Pan T; You T; Ruan C; Han Y
Semin Thromb Hemost; 2019 Nov; 45(8):767-777. PubMed ID: 31627217
[TBL] [Abstract][Full Text] [Related]
14. Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation.
Richardson PG; Smith AR; Kernan NA; Lehmann L; Soiffer RJ; Ryan RJ; Tappe W; Grupp S
Br J Haematol; 2020 Aug; 190(4):583-587. PubMed ID: 32157682
[TBL] [Abstract][Full Text] [Related]
15. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
[TBL] [Abstract][Full Text] [Related]
16. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
Corbacioglu S; Kernan N; Lehmann L; Brochstein J; Revta C; Grupp S; Martin P; Richardson PG
Expert Rev Hematol; 2012 Jun; 5(3):291-302. PubMed ID: 22780209
[TBL] [Abstract][Full Text] [Related]
17. A Meta-Analysis Evaluating the Incidence of Bleeding Events With Intravenous Defibrotide Treatment Outside the Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Setting.
Tappe W; Aggarwal S; Topaloglu O; Iacobelli M
Clin Appl Thromb Hemost; 2020; 26():1076029620935202. PubMed ID: 32687402
[TBL] [Abstract][Full Text] [Related]
18. Defibrotide in Severe Sinusoidal Obstruction Syndrome: Medicine and Economic Issues.
Steelandt J; Bocquet F; Cordonnier AL; De Courtivron C; Fusier I; Paubel P
Biol Blood Marrow Transplant; 2017 Feb; 23(2):347-356. PubMed ID: 27939616
[TBL] [Abstract][Full Text] [Related]
19. Defibrotide for the treatment of sinusoidal obstruction syndrome: evaluation of response to therapy and patient outcomes.
Coutsouvelis J; Avery S; Dooley M; Kirkpatrick C; Spencer A
Support Care Cancer; 2018 Mar; 26(3):947-955. PubMed ID: 29022099
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment with defibrotide for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation.
Yakushijin K; Matsui T; Okamura A; Yamamoto K; Ito M; Chihara K
Kobe J Med Sci; 2005; 51(3-4):55-65. PubMed ID: 16444097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
